No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VNDA240517C6000
- 0.25
- +0.05+25.00%
15min DelayClose May 8 15:59 ET
0.35High0.15Low
0.35Open0.20Pre Close362 Volume767 Open Interest6.00Strike Price8.99KTurnover152.19%IV17.07%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.25Time Value100Contract SizeAmericanOptions Type0.3614Delta0.2962Gamma19.49Leverage Ratio-0.0279Theta0.0004Rho7.04Eff Leverage0.0031Vega
Intraday
- 5D
- 1D
News
Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading aft
Express News | Vanda Pharmaceuticals Shares Down 7.1% Premarket After Q1 Loss Vs Year-Ago Profit
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Vanda Pharma Q1 2024 GAAP EPS $(0.07) Misses $0.05 Estimate, Sales $47.462M Miss $48.500M Estimate
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 by 240 percent. The company reported quarterly sales of $47.462 million
Express News | Vanda Pharmaceuticals Inc: Revenues for Q1 2024 Were $47.5 Mln
Comments
Future Pak's Strategic Move to Acquire Vanda Pharmaceuticals: A Comprehensive Analysis.
We found a bold and calculated maneuver, Future Pak LLC ("Future Pak") has stepped up its acquisition game by enhancing its offer for Vanda Pharmaceuticals Inc. ("Vanda" or "the Company"), signaling a pivotal moment in the pharmaceutical industry's mergers and acquisitions landscape. This revised proposal not only raises the cash consideration but notably...
We found a bold and calculated maneuver, Future Pak LLC ("Future Pak") has stepped up its acquisition game by enhancing its offer for Vanda Pharmaceuticals Inc. ("Vanda" or "the Company"), signaling a pivotal moment in the pharmaceutical industry's mergers and acquisitions landscape. This revised proposal not only raises the cash consideration but notably...
$Vanda Pharmaceuticals(VNDA.US$ Are you gonna go up for a bit more? Or will you fall like most of the market right now? Hehehe
$Vanda Pharmaceuticals(VNDA.US$ Benzinga· 7 mins ago
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
4
Read more